These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18528895)

  • 1. Levodopa therapy in a Lesch-Nyhan disease patient: pathological, biochemical, neuroimaging, and therapeutic remarks.
    Serrano M; Pérez-Dueñas B; Ormazábal A; Artuch R; Campistol J; Torres RJ; García-Cazorla A
    Mov Disord; 2008 Jul; 23(9):1297-300. PubMed ID: 18528895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters.
    Jankovic J; Caskey TC; Stout JT; Butler IJ
    Ann Neurol; 1988 May; 23(5):466-9. PubMed ID: 2455472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Lesch-Nyhan disease with S-adenosylmethionine: experience with five young Malaysians, including a girl.
    Chen BC; Balasubramaniam S; McGown IN; O'Neill JP; Chng GS; Keng WT; Ngu LH; Duley JA
    Brain Dev; 2014 Aug; 36(7):593-600. PubMed ID: 24055166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa is not a useful treatment for Lesch-Nyhan disease.
    Visser JE; Schretlen DJ; Bloem BR; Jinnah HA
    Mov Disord; 2011 Mar; 26(4):746-9. PubMed ID: 21506156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very Early Levodopa May Prevent Self-Injury in Lesch-Nyhan Disease.
    Visser JE; Chorin O; Jinnah HA
    Pediatr Neurol; 2024 Jun; 155():156-159. PubMed ID: 38653184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal adenosine and dopamine receptor expression in lymphocytes of Lesch-Nyhan patients.
    García MG; Puig JG; Torres RJ
    Brain Behav Immun; 2009 Nov; 23(8):1125-31. PubMed ID: 19635551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular, biochemical, and genetic characterization of a female patient with Lesch-Nyhan disease.
    Rinat C; Zoref-Shani E; Ben-Neriah Z; Bromberg Y; Becker-Cohen R; Feinstein S; Sperling O; Frishberg Y
    Mol Genet Metab; 2006 Mar; 87(3):249-52. PubMed ID: 16343967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is ZMP the toxic metabolite in Lesch-Nyhan disease?
    López JM
    Med Hypotheses; 2008 Nov; 71(5):657-63. PubMed ID: 18710792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The motor disorder of classic Lesch-Nyhan disease.
    Visser JE; Harris JC; Barabas G; Eddey GE; Jinnah HA
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1161-4. PubMed ID: 15571221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, post-mortem, biochemical and therapeutic observations on the Lesch-Nyhan syndrome with particular reference to the Neurological manifestations.
    Watts RW; Spellacy E; Gibbs DA; Allsop J; McKeran RO; Slavin GE
    Q J Med; 1982; 51(201):43-78. PubMed ID: 7111674
    [No Abstract]   [Full Text] [Related]  

  • 11. [Xanthinuria with xanthine lithiasis in a patient with Lesch-Nyhan syndrome under allopurinol therapy].
    Rebentisch G; Stolz S; Muche J
    Aktuelle Urol; 2004 Jun; 35(3):215-21. PubMed ID: 15258855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of secondary dystonia responding to levodopa.
    Bernard G; Vanasse M; Chouinard S
    J Child Neurol; 2010 Jun; 25(6):780-1. PubMed ID: 19808991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe pyridine nucleotide depletion in fibroblasts from Lesch-Nyhan patients.
    Fairbanks LD; Jacomelli G; Micheli V; Slade T; Simmonds HA
    Biochem J; 2002 Aug; 366(Pt 1):265-72. PubMed ID: 11996669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of neurological symptoms in Lesch-Nyhan disease: A systematic review.
    Krajewski O; Opiełka M; Urbanowicz K; Chojnowski K; Kochany P; Pawłowski K; Tomaszewska J; Peters GJ; Smoleński RT; Bełdzińska MM
    Neurosci Biobehav Rev; 2024 Oct; 165():105847. PubMed ID: 39117131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of L-5-hydroxytryptophan on self-mutilatin in Lesch-Nyhan disease: a negative report.
    Anderson LT; Herrmann L; Dancis J
    Neuropadiatrie; 1976 Nov; 7(4):439-42. PubMed ID: 1087383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the adenosinergic system in the brain of HPRT knockout mouse (Lesch-Nyhan disease).
    Bertelli M; Cecchin S; Lapucci C; Jacomelli G; Jinnah HA; Pandolfo M; Micheli V
    Clin Chim Acta; 2006 Nov; 373(1-2):104-7. PubMed ID: 16793031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered membrane NTPase activity in Lesch-Nyhan disease fibroblasts: comparison with HPRT knockout mice and HPRT-deficient cell lines.
    Pinto CS; Jinnah HA; Shirley TL; Nyhan WL; Seifert R
    J Neurochem; 2005 Jun; 93(6):1579-86. PubMed ID: 15935074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral aspects of Lesch-Nyhan disease and its variants.
    Schretlen DJ; Ward J; Meyer SM; Yun J; Puig JG; Nyhan WL; Jinnah HA; Harris JC
    Dev Med Child Neurol; 2005 Oct; 47(10):673-7. PubMed ID: 16174310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presynaptic dopaminergic deficits in Lesch-Nyhan disease.
    Ernst M; Zametkin AJ; Matochik JA; Pascualvaca D; Jons PH; Hardy K; Hankerson JG; Doudet DJ; Cohen RM
    N Engl J Med; 1996 Jun; 334(24):1568-72. PubMed ID: 8628337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards rational drug treatment of Lesch-Nyhan disease.
    Seifert R
    Mol Genet Metab; 2016 Jul; 118(3):145-146. PubMed ID: 27216368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.